Spruce Biosciences, Inc. Cash and Restricted Cash
Spruce Biosciences, Inc. (SPRB) had Cash and Restricted Cash of $96.33 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $96.33M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.12M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.94M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.70M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $96.33M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $54.12M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $48.94M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $10.70M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $16.42M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $25.65M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $38.79M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $60.09M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $69.72M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $81.19M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $96.37M 10-K · filed 2026-03-09 |
| 2023-09-30 | $98.83M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $97.52M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $73.95M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $24.73M 10-K · filed 2025-04-15 |
| 2022-09-30 | $21.86M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $47.43M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $23.56M 10-Q · filed 2023-05-15 |
| 2021-12-31 | $42.96M 10-K · filed 2024-03-18 |
| 2021-09-30 | $58.58M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $78.49M 10-Q · filed 2022-08-10 |
| 2021-03-31 | $148.84M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $157.37M 10-K · filed 2023-03-16 |
| 2020-09-30 | $72.37M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $36.82M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $41.62M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $3.92M 10-K · filed 2021-03-22 |
| 2019-09-30 | $4.83M 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |